Effect of pharmacological therapies for glycemic control in patients with type 2 diabetes mellitus on vascular outcomes
PDF (Español (España))
HTML (Español (España))


Liraglutide, empagliflozin; vascular diseases; diabetes mellitus, type 2; hypoglycemic agents.

How to Cite

Lopera Vargas JM, Rico Fontalvo JE, Melgarejo R. E, Castillo Barrios GA, Ramírez Rincón A, Gomez AM, Martínez Rojas S, Ibatá Bernal L. Effect of pharmacological therapies for glycemic control in patients with type 2 diabetes mellitus on vascular outcomes. Rev. Colomb. Nefrol. [Internet]. 2020 Mar. 2 [cited 2021 Dec. 7];7(1). Available from: https://www.revistanefrologia.org/index.php/rcn/article/view/372


Introduction: In the last 5 years the publication of knowledge related to vascular disease and diabetes mellitus type 2 (DT2) has been increasing. However, due to the absence of a review that collects all the vascular outcomes of T2D, the current review of the literature aims to group all vascular outcomes related to T2D and describe how hypoglycemic drug therapy can be effective for the control of these outcomes. Cardiovascular events as the main outcome show that innovative antidiabetic drugs such as empagliflozin and liraglutide can add significant benefits for patients with T2D.

Materials and methods: Systematic search of the literature, from which 141 references were obtained, after eliminating duplicates, for paired screening. Subsequently, 21 references were identified that met the inclusion criteria to be considered in the analysis.

Results: The effect of good glycemic control on clinical outcomes, specifically in the progression of diabetic kidney disease, has been the objective of multiple large-scale studies, both in type 1 diabetic patients and type 2 diabetics and macrovascular outcome of the primary DMT2, increasing the incidence of comorbidities and in turn representing greater morbidity.

Conclusions: Among the main causes of morbidity and mortality of patients with T2D, are those with vascular damage, especially cardiovascular disease and renal involvement. In this context, the pharmacological treatment of diabetes mellitus has focused on finding drugs that reduce the importance of cardiovascular events and that at the same time delay the onset of nephropathy or its progression. Thiazolidinediones, DPP4 inhibitors (alogliptin, saxagliptin and sitagliptin), insulin glargine and degludec have demonstrated cardiovascular safety, but not incremental cardiovascular benefits, in patients with T2D who are at high risk of atherosclerotic cardiovascular disease.

PDF (Español (España))
HTML (Español (España))


Schernthaner G, Lehmann R, Prázný M, et al. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: Recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol. 2017;16(1):137. https://doi:10.1186/s12933-017-0622-7

Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5(1):57. https://doi:10.1186/1758-5996-5-57

Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4(6):537-547. https://doi:10.1016/ S2213-8587(16)30010-9

IDF. IDF diabetes atlas - 2017 Atlas. IDF Diabetes Atlas.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

CDCP. National estimates and general information on diabetes and prediabetes in the US. http//www/caldiabetes org/content_display cfm? FontSize= Norm 562&CategoriesID= 31. Published online 2011. http://ndep.nih.gov/media/fs_gensnapshot.pdf

Vrsalovi? M, Vu?ur K. Diabetes, renal dysfunction, inflammation, and anemia: the deadly quartet in peripheral artery disease. Endocr Oncol Metab. 2016;2(1):82-87. https://doi:10.21040/eom/2016.2.9

Booth GL, Kapral MK, Fung K, Tu J V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29-36. https://doi:10.1016/S0140-6736(06)68967-8

Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 34(31):2436-2443.

Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222.https://doi:10.1016/S0140-6736(10)60484-9

Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. Jama. 2015;314(1):52-60.

Tejada García J, Redondo Robles L. Epidemiología de la enfermedad vascular cerebral en los pacientes con diabetes. Av en Diabetol. 2010;26(6):397-402. https://doi:10.1016/S1134-3230(10)66003-6

Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. Am J Cardiol. 2017;120(1):S37-S47. https://doi:10.1016/j.amjcard.2017.05.014

Vásquez EM, Burbano Á, Ibáñez CI, et al. Panel nacional de expertos sobre la atención de la cardiomiopatía diabética. Rev la ALAD. 2016;6(4):170-180. https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120221110&site=ehost-live

Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA - J Am Med Assoc. 2016;316(6):602-610. https://doi:10.1001/jama.2016.10924

Van Dieren S, Beulens JWJ, Van Der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010;17(SUPPL. 1):S3-8. https://doi:10.1097/01.hjr.0000368191.86614.5a

Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208-230. https://doi:10.1093/ndt/gfy407

Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J. 2000;321(7258):405-412. https://doi:10.1136/bmj.321.7258.405

Hamish M, Gohel MS, Davies AH. Peripheral arterial disease in patients with diabetes mellitus. Br J Hosp Med. 2008;69(10):570-574. https://doi:10.12968/hmed.2008.69.10.31316

Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. Clin Cardiol. 2017;40(5):287-291. https://doi:10.1002/clc.22657

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Rev Esp Cardiol. 2020;73(5):404.e1-404.e59.


Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, Mcguire DK. Cardiovascular risk in diabetes mellitus: Complication of the disease or of antihyperglycemic medications. Clin Pharmacol Ther. 2015;98(2):145-161. https://doi:10.1002/cpt.143

Rodríguez-Segade S, Rodríguez J, Paz JM, Camiña F. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2009;32(1):1473-1478. https://doi:10.2337/dc08-1214

Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care. 2010;33(5):1090-1096. https://doi:10.2337/dc09-1941

1. Improving care and promoting health in populations: Standards of medical care in diabetesd2019. Diabetes Care. 2019;42(Supplement 1):S7-S12. https://doi:10.2337/dc19-S001

Conlin PR, Colburn J, Aron D, Pries RM, Tschanz MP, Pogach L. Synopsis of the 2017 U.S. Department of veterans affairs/ U.S. Department of defense clinical practice guideline: Management of type 2 diabetes mellitus. Ann Intern Med. 2017;167(9):655-663. https://doi:10.7326/M17-1362

Standl E, Schnell O, McGuire DK, Ceriello A, Rydén L. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5(5):391-402. https://doi:10.1016/S2213-8587(17)30033-5

Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: A new cardiovascular risk factor? Heart. 2014;100(1):21-27. https://doi:10.1136/heartjnl-2013-303871

Wright RJ, Frier BM. Vascular disease and diabetes: Is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353-363. https://doi:10.1002/dmrr.865

Bertoluci MC, Moreira RO, Faludi A, et al. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: A position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017;9(1):53. https://doi:10.1186/s13098-017-0251-z

Graham I, Ata D, Borch-Johnsen K, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Ending). Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Ration Pharmacother Cardiol. 2008;4(4):90-107. https://doi:10.20996/1819-6446-2008-4-4-90-107

Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American diabetes association. Diabetes Care. 2015;38(9):1777-1803. https://doi:10.2337/dci15-0012

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patientswith type 2 diabetes and kidney disease a systematic review. JAMA - J Am Med Assoc. 2014;312(24):2668-2675. https://doi:10.1001/jama.2014.15298

Carlos A. Tiazolidinedionas. Beneficios y riesgos reales. Rev Endocrinol y Nutr Abril-Junio. 2002;10(2):69-76. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21251997000600014

Agudelo-Zapata Y, Burgos-Cárdenas ÁJ, Díaz-Martínez ÁJ, Pinilla-Roa AE. Dipeptidil dipeptidase-IV inhibidors: From the theory to the practice. Rev Fac Med. 2015;63(2):259-270. https://doi:10.15446/revfacmed.v63n2.48820

Arocha Rodulfo JI, Amair P, Marantes D, Navas Blanco T. El papel del riñón en la homeostasis de la glucosa y drogas de acción renal en el tratamiento de la diabetes mellitus tipo 2^ies. Med interna. 2016;32(2):78-88.

Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. https://doi:10.1056/NEJMoa1203858

Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1. Am Heart J. 2016;179:175-183. https://doi:10.1016/j.ahj.2016.06.004

Marso SP, Mcguire DK, Zinman B, et al. Efficacy and safety of degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. https://doi:10.1056/NEJMoa1615692

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obes Metab. 2017;19(4):524-536. https://doi:10.1111/dom.12849

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin- Dependent Diabetes Mellitus. N Engl J Med. 1993;329(14):977-986. https://doi:10.1056/NEJM199309303291401

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. Am J Ophthalmol. 2000;129(5):704-705. https://doi:10.1016/s0002-9394(00)00453-0

Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117. https://doi:10.1016/0168-8227(95)01064-K

Lund SS, Rossing P, Vaag AA. Follow-up of intensive glucose control in type 2 diabetes [1]. N Engl J Med. 2009;360(4):416-418. https://doi:10.1056/NEJMc082275

Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865. https://doi:10.1016/S0140-6736(98)07037-8

Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853. https://doi:10.1016/S0140-6736(98)07019-6

Ceriello A. La “memoria metabólica” inducida por la hiperglucemia: el nuevo reto en la prevención de la enfermedad cardiovascular en la diabetes. Rev Española Cardiol Supl. 2008;8(3):12C-18C. https://doi:10.1016/s1131-3587(08)73550-7

Ismail-Beigi F, Craven T, Banerji MA. Erratum: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial (The Lancet (2010) 376 (419-430)). Lancet. 2010;376(9751):1466. https://doi:10.1016/S0140-6736(10)61995-2

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. J Vasc Surg. 2008;48(3):770. https://doi:10.1016/j.jvs.2008.07.045

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. https://doi:10.1056/NEJMoa0808431

Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620-1629. https://doi:10.1007/s00125-017-4337-9

Kalra S, Gupta Y, Baruah MP, Gupta A. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes care 2015;38:696-705. Diabetes Care. 2015;38(6):e88- e89. https://doi:10.2337/dc15-0006

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. https://doi:10.1056/NEJMoa1307684

Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076. https://doi:10.1016/S0140-6736(14)62225-X

Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care. 2016;39(12):2304-2310. https://doi:10.2337/dc16-1415

Sattar N, Petrie MC, Zinman B, Januzzi JL. Novel Diabetes Drugs and the Cardiovascular Specialist. J Am Coll Cardiol. 2017;69(21):2646-2656. https://doi:10.1016/j.jacc.2017.04.014

Kankanala SR, Syed R, Gong Q, Ren B, Rao X, Zhong J. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: Recent evidence on heart failure. Am J Transl Res. 2016;8(5):2450-2458.

Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Postgrad Med. 2018;130(2):149-153. https://doi:10.1080/00325481.2018.1423852

Saad M, Mahmoud AN, Elgendy IY, et al. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017;228:352-358. https://doi:10.1016/ j.ijcard.2016.11.181

Hinnen D. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2015;6(3):92-102. https://doi:10.1177/2042018815575273

Gargiulo P, Savarese G, D’Amore C, et al. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis. 2017;27(12):1081-1088. https://doi:10.1016/ j.numecd.2017.09.006

Wong C, Fisher M. Inconclusive effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. Pract Diabetes. 2017;34(9):302-303. https://doi:10.1002/pdi.2140

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.


Download data is not yet available.